| Current Quote* |
| Last: | $6.810 |
| Volume: | 19,941,183 |
As Of: 2013-05-23 13:38:49 ET *Quotes delayed by 20min. |
|
Mannkind Corp (NASDAQ:MNKD) Industry: Healthcare
MannKind Corporation, a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate, AFREZZA inhalation powder, an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
|